This compound, (2S)-5-(Cyclohexyloxy)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-5-oxopentanoic acid, is a protected amino acid derivative. Its structure features an L-glutamic acid core where the alpha-amino group is protected by a 9-fluorenylmethoxycarbonyl (Fmoc) group, a standard protecting group in peptide synthesis. The side-chain carboxylic acid is esterified with cyclohexanol, forming a cyclohexyl ester. This specific protection pattern makes it a non-natural, synthetic building block. Its primary and well-defined application is in solid-phase peptide synthesis (SPPS) as a specialized, protected glutamic acid derivative. The Fmoc group is selectively removable under mild basic conditions, allowing for the sequential elongation of peptide chains. The cyclohexyl ester on the side chain provides orthogonal protection, which can be cleaved under different conditions (typically acidic) than the Fmoc group, enabling precise control over the synthesis of peptides containing glutamic acid. It is therefore a crucial “drug synthesis building block” for constructing peptide-based active pharmaceutical ingredients (APIs) and peptide fragments for research. As a designed, protected amino acid, it is not a naturally occurring substance or a final API. Its sole purpose is to serve as a high-purity, synthetic intermediate. Consequently, it is categorized foremost as a pharmaceutical intermediate and secondarily as a specialized organic synthesis building block due to its specific, application-driven structure.